GlassScriptPhysician profile
Harry S Abram
NPI 1427069947
$7,689.70
in general payments reported to CMS, 2019-2025
10 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $6,011 · 2021: $493 · 2023: $197 · 2024: $22.63 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $7,197.69 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $195.34 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $94.29 | 2019 | |
| Ucb, INC. | $64.09 | 2025 | Briviact |
| Neurelis, INC. | $46.24 | 2025 | Valtoco |
| Otter Pharmaceuticals, LLC | $25.65 | 2025 | Sympazan |
| Acadia Pharmaceuticals INC | $24.77 | 2023 | Daybue |
| Zogenix INC. | $21.19 | 2021 | |
| Sarepta Therapeutics, INC. | $20.44 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Abram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.